Actively Recruiting
Aneurysmal Subarachnoid Hemorrhage Multi-Omics Research Program
Led by Xiaolin Chen, MD · Updated on 2025-12-08
2000
Participants Needed
1
Research Sites
213 weeks
Total Duration
On this page
Sponsors
X
Xiaolin Chen, MD
Lead Sponsor
P
Peking Union Medical College
Collaborating Sponsor
AI-Summary
What this Trial Is About
Aneurysmal subarachnoid hemorrhage (aSAH) is a life-threatening cerebrovascular emergency with high mortality and disability rates. Despite advances in neuroimaging and interventional techniques, outcomes remain poor for many patients due to complex post-rupture complications such as delayed cerebral ischemia (DCI), pneumonia, and other systemic injuries. These secondary events critically affect neurological recovery, yet their molecular mechanisms are not fully understood. This multicenter study aims to investigate the biological basis of post-rupture complications and prognosis in patients with aSAH through integrated multi-omics and clinical data analysis. Biospecimens including blood, cerebrospinal fluid, urine, and other relevant tissues will be collected for genomic, transcriptomic, proteomic, metabolomic, and imaging-omic profiling. By linking molecular data with clinical and imaging indicators, the study seeks to identify key pathways and biomarkers associated with secondary injury and outcome heterogeneity.
CONDITIONS
Official Title
Aneurysmal Subarachnoid Hemorrhage Multi-Omics Research Program
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients aged 6518 years
- Confirmed diagnosis of aneurysmal subarachnoid hemorrhage (aSAH) by CTA or DSA
- Aneurysm treated by microsurgical clipping or endovascular coiling during hospitalization
- Time from onset to aneurysm treatment 64 72 hours
- Availability of biospecimens including blood, cerebrospinal fluid, urine, or fecal samples collected during hospitalization
- Signed informed consent from the patient or legal representative
You will not qualify if you...
- History of previous intracranial aneurysm surgery or embolization
- Non-aneurysmal SAH, traumatic SAH, or perimesencephalic non-aneurysmal hemorrhage
- Presence of malignancy, severe liver or kidney dysfunction, or other systemic diseases affecting survival or biomarker expression
- Severe heart or lung failure or unstable medical condition preventing study participation
- Pregnancy or breastfeeding
- Refusal to participate or withdrawal of consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Tiantan Hospital
Beijing, Beijing Municipality, China, 100070
Actively Recruiting
Research Team
R
Runting Li, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here